HUMA vs. VERA, TVTX, EWTX, EVO, BHVN, MESO, ANIP, HROW, PAHC, and ABCL
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Vera Therapeutics (VERA), Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), Evotec (EVO), Biohaven (BHVN), Mesoblast (MESO), ANI Pharmaceuticals (ANIP), Harrow (HROW), Phibro Animal Health (PAHC), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs. Its Competitors
Vera Therapeutics (NASDAQ:VERA) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.
Humacyte has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Humacyte's return on equity of 0.00% beat Vera Therapeutics' return on equity.
99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 16.3% of Vera Therapeutics shares are held by company insiders. Comparatively, 5.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Vera Therapeutics currently has a consensus target price of $65.00, indicating a potential upside of 182.00%. Humacyte has a consensus target price of $11.71, indicating a potential upside of 402.76%. Given Humacyte's higher possible upside, analysts plainly believe Humacyte is more favorable than Vera Therapeutics.
Vera Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.
In the previous week, Vera Therapeutics and Vera Therapeutics both had 4 articles in the media. Vera Therapeutics' average media sentiment score of 0.34 beat Humacyte's score of -0.05 indicating that Vera Therapeutics is being referred to more favorably in the media.
Summary
Vera Therapeutics and Humacyte tied by winning 7 of the 14 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 7/21/2025 by MarketBeat.com Staff
